Nutcracker Therapeutics announced three new leadership hires, including John Stubenrauch as COO and Geoff Nosrati as chief business officer.
Stubenrauch brings 25 years of experience in biopharma, including a stint as VP of biologics commercial operations at Gilead Sciences. Before that, he served as a site general manager at AstraZeneca and held roles at Merck.
“John brings invaluable leadership and industry experience to Nutcracker Therapeutics as the company continues taking decisive steps toward realizing the therapeutic potential of RNA for patients across multiple oncology indications,” said Nutcracker CEO Igor Khandros in a statement. “His track record of strategic product executions within the biopharmaceutical industry should prove instrumental in guiding our growth in the years to come.”
Nosrati joins Nutcracker from Immunoscape, where he served as chief business officer. Before that, he was SVP of strategy and corporate development at Aduro Biotech.
In addition, Ian Weiner is joining as general counsel, where he’ll advise the company’s board and management on legal and business issues. Weiner joins from his role as a partner at Irell & Manella.
The announcement comes three months after Nutcracker brought in $167 million in Series C funding. The company is currently developing three mRNA drug candidates for HPV-driven tumors, T cell lymphoma and genitourinary tumors.
